Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (19): 3471-3476.doi: 10.3969/j.issn.1673-8225.2010.19.011

Previous Articles     Next Articles

Mechanisms underlying intravenous transplantation of human amniotic mesenchymal stem cells for Alzheimer’s disease in transgenic APP+ mice

Wang Cheng-chun1,2, Yang Bo2,3, Guan Fang-xia1, Li Guo-dong4, Zhou Chang-hui1,2, Zhou Yun-fan1, Hu Xiang5,6, Gu Chen-xi7, Lei Ning-jing1   

  1. 1Department of Bioengineering, Zhengzhou University, Zhengzhou  450001, Henan Province, China;
    2Opening Laboratory of Major Subjects, Henan Institute of Clinical Medicine, Zhengzhou 450052, Henan Province, China;
    3Department of Neurosurgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou  450052, Henan Province, China;
    4Medical Experimental Center, Zhengzhou University, Zhengzhou  450052, Henan Province, China;
    5Jiangsu Public Technology Service Platform of Stem Cells and Biotherapy, Taizhou  225300, Jiangsu Province, China;
    6Shenzhen Beike Cell Engineering Institute, Shenzhen  518000, Guangdong Province, China;
    7Department of Clinical Medicine, Zhengzhou University, Zhengzhou  450001, Henan Province, China
  • Online:2010-05-07 Published:2010-05-07
  • Contact: Guan Fang-xia☆, Doctor, Professor, Department of Bioengineering, Zhengzhou University, Zhengzhou 450001, Henan Province, China guanfangxia@126.com
  • About author:Wang Cheng-chun★, Studying for master's degree, Department of Bioengineering, Zhengzhou University, Zhengzhou 450001, Henan Province, China; Opening Laboratory of Major Subjects, Henan Institute of Clinical Medicine, Zhengzhou 450052, Henan Province, China springreen@126.com Yang Bo★, Master, Professor, Doctoral supervisor, Opening Laboratory of Major Subjects, Henan Institute of Clinical Medicine, Zhengzhou 450052, Henan Province, China; Department of Neurosurgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, Henan Province, China yangbo96@126.com Wang Cheng-chun and Yang Bo contributed equally to this work.
  • Supported by:

    Third-stage Construction Project of 211 Program in Zhengzhou University*;
    the Science and Technology Development Project of Department of Science and Technology of Henan Province in 2009, No. 092102310250*;
    the Public Technical Service Platform of Stem Cell and Biotherapy of Jiangsu Province, No. BM2008146*

PDF

521

Abstract:

BACKGROUND: APP gene is closely associated with the onset of Alzheimer’ disease. Intravenous transplantation of human amniotic mesenchymal stem cell (AMSCs) can promote the learning and memory improvement in transgenic APP+ mice with Alzheimer’ disease.
OBJECTIVE: To study whether the AMSCs can transfer into the brain tissue of Alzheimer’s disease mice, and differentiate into the neural cell, then cure the disease after the human AMSC transplantation via tail venous injection.
METHODS: Human AMSCs were isolated in vitro sterilely. At the third passage, 0.5 mL single cell suspension at 1×109/L was obtained and transplanted by tail venous pathway in transplantation group mice, Mice in the control group were injected with an equal volume of saline. APP-gene mice in the normal group were left intact. 5’-bromo-2-deoxyuridine (BrdU) labeled third-generation AMSCs expression was detected in mice brain tissue by immunohistochemical method. Glial fibrillary acidic protein (GFAP), Nestin and neuron specific enolase (NSE) expression was measured in the brain tissue of mice from each group.
RESULTS AND CONCLUSION: Under an optical microscope, a majority of nuclei in the brain tissue of mice from transplantation group were stained blue, but some nuclei were stained brown, positive for BrdU. Compared with control group, the expression of GFAP in the brain tissue of transplanted mice was increased about 4 times, even more than in the normal group (P < 0.05). The expression of Nestin in the brain tissue of transplanted mice was increased about 10%, but still lower than the normal group nearly 20% (P < 0.05). NSE expression was decreased by 1/3, but still higher compared with the normal group (P < 0.05). Above-mentioned results have shown that human AMSC transplantation for treating Alzheimer’s disease takes place by AMSCs homing to APP+ mouse brain tissue and differentiating into neural cells.

CLC Number: